Accelerate Diagnostics (AXDX) Earns Daily Media Impact Rating of 0.03
Media headlines about Accelerate Diagnostics (NASDAQ:AXDX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Accelerate Diagnostics earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 45.4561076889919 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
AXDX has been the topic of several analyst reports. Zacks Investment Research downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. BTIG Research downgraded Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research report on Wednesday. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the stock. Accelerate Diagnostics presently has an average rating of “Hold” and an average target price of $33.00.
Accelerate Diagnostics (AXDX) opened at $27.25 on Friday. Accelerate Diagnostics has a 52-week low of $16.75 and a 52-week high of $30.45.
In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 276,200 shares of the stock in a transaction dated Thursday, October 12th. The shares were acquired at an average cost of $19.74 per share, for a total transaction of $5,452,188.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jack W. Schuler acquired 5,500 shares of the stock in a transaction dated Friday, November 17th. The stock was acquired at an average price of $22.00 per share, for a total transaction of $121,000.00. The disclosure for this purchase can be found here. Insiders have purchased 981,667 shares of company stock worth $18,879,924 over the last quarter. 50.00% of the stock is owned by company insiders.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with Analyst Ratings Network's FREE daily email newsletter.